Cisplatin or carboplatin for the treatment of non-small cell lung cancer: do they have equivalent efficacy?
- 1 October 2001
- journal article
- editorial
- Published by Elsevier in Lung Cancer
- Vol. 34 (1) , 15-17
- https://doi.org/10.1016/s0169-5002(01)00240-9
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Survival advantage for carboplatin substituting cisplatin in combination with vindesine and mitomycin C for stage IIIB and IV squamous-cell bronchogenic carcinoma: a randomized phase III studyLung Cancer, 2001
- Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancerBritish Journal of Cancer, 2000
- A comparison of methods of calculation for estimating carboplatin AUC with a retrospective pharmacokinetic-pharmacodynamic analysis in patients with advanced non-small cell lung cancerEuropean Journal Of Cancer, 1999
- Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trialsBMJ, 1995
- A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861.Journal of Clinical Oncology, 1990